capital raise

(NYSE:OSCR) NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (“Oscar”) (NYSE: OSCR) today announced the pricing of its offering of $355,000,000 aggregate principal amount of 2.25% convertible senior subordinated notes due 2030 (the “notes”) in a private offering (the “Offering”) to qualified investors.1 The offering size was increased from the previously announced offering size of $350,000,000 aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on September 18, 2025

Tonner Drones announces the launch of a capital increase with preferential subscription rights in the form of ABSA for a maximum amount of approximately 1 million euros

HAMILTON, Bermuda--(BUSINESS WIRE)--MultiStrat, the specialist underwriter and reinsurance investment platform, has announced a new capital investment by a large institutional asset manager in a reinsurance vehicle established and managed by MultiStrat. MultiStrat has entered into a definitive agreement to provide underwriting and liability management services for a casualty reinsurance-focused reinsurance vehicle established by MultiStrat for a large alternative asset manager with over $100bn

(NASDAQ:ARTL) SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced it has commenced an underwritten public offering of its common stock and/or pre-funded warrants. All shares of common stock and/or pre-funded warrants in the offering are to be offered by the Company. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

(NASDAQ:BRKR) BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (“Bruker”) (Nasdaq: BRKR) today announced it has commenced a public offering, subject to market and other conditions, of $600.0 million of Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock”). Bruker expects to grant the underwriters a 30-day option to purchase up to an additional $90.0 million of Mandatory Convertible Preferred Stock, solely to cover over-allotments, if any

(NASDAQ:TRON) Winter Park, Florida, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tron Inc. (Nasdaq: TRON) (the “Company”), an innovation leader at the intersection of blockchain, entertainment, and digital assets, today announced the expansion of its TRON (TRX) token treasury holdings to over $220 million.

Transaction could raise up to $1 billion in aggregate gross proceeds if all of the warrants are exercised, which would make Sharps Technology one of the largest Solana treasury companies Subscribers included preeminent financial institutions and digital asset market leaders such as...

NEW YORK, Aug. 28, 2025 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) today announced the filing of its shelf registration statement (the "Shelf Registration") on Form S-3 with the U.S. Securities and Exchange Commission (the "SEC"). If the Shelf Registration is declared...

- The offering was made to two new fundamental institutional investors -

INCLINE VILLAGE, Nev., Aug. 25, 2025 /PRNewswire/ -- Phinge Corporation today announced its intention to gauge market interest for a potential Regulation A+ offering, referred to as "testing the waters" under SEC Rule 255. This "test the waters" campaign will allow Phinge Corporation to...

WEST PALM BEACH, Fla.--(BUSINESS WIRE)--RiverNorth Opportunities Fund, Inc. (NYSE: RIV) (the “Fund”) announces that its Board of Directors (the “Board”) has authorized and set the terms of an offering to the Fund’s common stockholders of rights to purchase additional shares of common stock of the Fund. In this offering, the Fund will issue transferable subscription rights (“Rights”) to its common stockholders of record as of September 11, 2025 (the “Record Date” and such stockholders, “Record D

Proceeds Intended to Support the Company's Growth Strategy; the Offering Generated Strong Demand from Leading Institutional Investors CAESAREA, Israel, Aug. 25, 2025 /PRNewswire/ -- The Turpaz Industries group (TASE: TRPZ), a leading global company that develops, manufactures, markets,...

BOCA RATON, FL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced that it has entered into definitive agreements for a $125 million equity offering priced at $12.50 per share. The transaction is expected to close on Thursday, August 28, 2025, subject to customary closing conditions.

Reference is made to IDEX Biometrics ASA's disclosure on 21 July 2025 of a private placement of 9,090,909 shares at NOK 3.30 per share, split in two tranches. IDEX discloses the following information on behalf of primary insiders.

Top Win International (Nasdaq: SORA) Raises USD 10m, with Wiselink Co., Ltd. (TW: 8932) Leading the Raise as the First Taiwanese Public Company to Invest in a Bitcoin Treasury Company

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten offering of 21,250,000 shares of its common stock at an offering price of $4.00 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by Aquestive, are expected to be $85 million. The Company intends to use the net proceeds received from the offering, together with the Company’s existing cash and cash equivalents, primarily to advance the launch and commercialization of Anaphylm™ (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis, assuming United States Food and Drug Administration (FDA) approval, and fo

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Compass are expected to be approximately $120 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about August 14, 2025, subject to custom

LOS ANGELES, Aug. 8, 2025 /PRNewswire/ -- Thumzup Media Corporation (Nasdaq: TZUP) ("Thumzup" or the "Company"), a digital asset accumulator and advertising industry disruptor, today announced that it has commenced a best efforts public offering of shares of its newly designated Series D...

Majority of net proceeds from offering will support purchases of Toncoin, the native cryptocurrency of The Open Network (“TON”) blockchain Majority of net proceeds from offering will support purchases of Toncoin, the native cryptocurrency of The Open Network (“TON”) blockchain